Fresenius said on Oct 1 it had bought the remaining 45% of biosimilars maker mAbxience for up to EUR750m in cash.
Market context
Fresenius first bought 55% in 2022. mAbxience had more than EUR320m of revenue in 2025 and over 1,300 staff.
Sources
Fresenius takes full control of mAbxience for up to EUR750m
Fresenius took full ownership of biosimilars maker mAbxience by buying the remaining 45% for up to €750m.
M&A News deals desk
